SLC5A2 and type 2 diabetes mellitus: Because T2DM can lead to DED and both diseases affect a large population, whether SGLT2 inhibitors can be employed as a straightforward strategy to reduce the incidence and severity of DED in patients with T2DM warrants exploration.